Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
Eyal Rubin, the Company's Sr. Vice President and Chief Financial Officer, will deliver a company presentation and be available for one-on-one investor meetings throughout the event.
Investors interested in scheduling a meeting with the Company's management team should contact their H.C. Wainwright representative or email meetings@hcwco.com.
Event Details
Conference: 3rd Annual H.C. Wainwright BioConnect Investor Conference
Date: Tuesday, May 20, 2025
Location: Nasdaq World Headquarters in New York City (151 W. 43rd Street)
Webcast Details
A webcast of the live presentation will be available at 4:30 pm, Eastern Daylight Time (EDT), via the following links:
Company Link: https://ir.protalix.com/news-events/events
Webcast Link: https://journey.ct.events/view/c15f7813-e688-4a3e-911e-358a9c0562b8
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights. Protalix's second product, Elfabrio®, was approved by both the FDA and the European Medicines Agency in May 2023.
Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX–119, a plant cell-expressed long acting DNase I for the treatment of NETs-related diseases; and others.
Investor Contact: Mike Moyer, Managing DirectorLifeSci Advisors+1-617-308-4306 mmoyer@lifesciadvisors.com
Logo: https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-present-at-the-3rd-annual-hc-wainwright-bioconnect-investor-conference-at-nasdaq-nyc-302455102.html
SOURCE Protalix BioTherapeutics, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Generational Group Advises The Rockwall Center of Sensory Integration, Inc. dba Excel Pediatric Therapy in its Sale to an Individual Investor
DALLAS, July 29, 2025--(BUSINESS WIRE)--Generational Group, a leading mergers and acquisitions advisory firm for privately held businesses, is pleased to announce the sale of The Rockwall Center of Sensory Integration, Inc. dba Excel Pediatric Therapy to an Individual Investor. The acquisition closed June 27, 2025. Based in Rockwall, Texas, The Rockwall Center of Sensory Integration, Inc. dba Excel Pediatric Therapy offers comprehensive physical, occupational, and speech therapy for children from birth up to seventeen years old. Founded and operated by experienced physical therapists with over 40 years of combined expertise, the clinic treats a range of neurological, orthopedic, and developmental conditions—such as sensory processing disorders, autism, ADHD, cerebral palsy, and feeding issues—using both innovative and traditional tools. With a highly trained staff and a state-of-the-art facility, Excel Pediatric Therapy is committed to intensive treatment, caregiver education, and creating enjoyable therapy environments that promote sustainable progress. Whether families are seeking early intervention or long-term support, Excel Pediatric Therapy works to "make a difference…one child at a time." Generational Group Executive Managing Director, M&A, Central Region – Michael Goss, and his team led by Vice President, M&A, Jacob Mangalath successfully closed the deal. Senior Managing Director, Doug Morrow and Senior M&A Advisor, Mike Moore, established the initial relationship with The Rockwall Center of Sensory Integration, Inc. dba Excel Pediatric Therapy. Ryan Binkley, CEO of Generational Group, stated, "We're committed to delivering results that generate long-term value for all stakeholders. This milestone reflects the effectiveness of our strategy and the trust our clients consistently place in us." About Generational Group Generational Group, headquartered in Dallas, TX, is a leading, award winning full-service M&A advisory firm. Generational has over 300 professionals across 16 offices in North America. The firm empowers business owners to unlock the full value of their companies through a comprehensive suite of services—including strategic growth consulting, exit planning education, business valuation, value enhancement strategies, M&A advisory, digital solutions, and wealth management. Celebrating its 20th year, Generational has successfully closed over 1,700 transactions and has ranked #1 or #2 in all LSEG league tables for deals valued between $25 million and $1 billion in 2022, 2023, and 2024. The firm was named 2024 USA Investment Banking Firm of the Year by the Global M&A Network and recognized as Investment Banking Firm of the Year by The M&A Advisor in both 2024 and 2022. View source version on Contacts Media Contact:Catherine Binkley469-828-2798cbinkley@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
Amazon (AMZN) Price Target Raised to $271 — Here's What's Driving It
Inc. (NASDAQ:AMZN) is one of the . On July 28, UBS analyst Stephen Ju raised the price target on the stock to $271.00 (from $249.00) while maintaining a Buy rating. The price target increase reflects UBS's decision to roll back some of the decreases in estimates it had made three months ago when it was expecting increased demand destruction from tariffs. The firm has raised its Gross Merchandise Value (GMV) estimates for 2026 by an estimated 2%, along with a 2% increase in gross profit projections. Moreover, it has also raised its 2026 and 2027 advertising segment forecasts by an estimated 3% due to better-than-expected advertising performance. Meanwhile, AWS growth estimates were maintained at 16% for the second quarter of 2025. 25 best things to buy on Amazon under $20 (Photo credit: Pixabay) Based on the revisions, there is a 1% increase in 2026 revenue estimates and a 5% increase in EBIT (Earnings Before Interest and Taxes) projections. For the year 2027, the firm projects a 0.1% revenue increase and a 7% EBIT increase. The firm also raised its 2025 CapEx forecast to $112 billion from the previous $107 billion after the company disclosed its first-quarter 2025 capital expenditures. Inc. (NASDAQ:AMZN) is an American technology company offering e-commerce, cloud computing, and other services, including digital streaming and artificial intelligence solutions. While we acknowledge the potential of AMZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.
Business Wire
41 minutes ago
- Business Wire
Generational Group Advises The Rockwall Center of Sensory Integration, Inc. dba Excel Pediatric Therapy in its Sale to an Individual Investor
DALLAS--(BUSINESS WIRE)-- Generational Group, a leading mergers and acquisitions advisory firm for privately held businesses, is pleased to announce the sale of The Rockwall Center of Sensory Integration, Inc. dba Excel Pediatric Therapy to an Individual Investor. The acquisition closed June 27, 2025. Based in Rockwall, Texas, The Rockwall Center of Sensory Integration, Inc. dba Excel Pediatric Therapy offers comprehensive physical, occupational, and speech therapy for children from birth up to seventeen years old. Founded and operated by experienced physical therapists with over 40 years of combined expertise, the clinic treats a range of neurological, orthopedic, and developmental conditions—such as sensory processing disorders, autism, ADHD, cerebral palsy, and feeding issues—using both innovative and traditional tools. With a highly trained staff and a state-of-the-art facility, Excel Pediatric Therapy is committed to intensive treatment, caregiver education, and creating enjoyable therapy environments that promote sustainable progress. Whether families are seeking early intervention or long-term support, Excel Pediatric Therapy works to 'make a difference…one child at a time.' Generational Group Executive Managing Director, M&A, Central Region – Michael Goss, and his team led by Vice President, M&A, Jacob Mangalath successfully closed the deal. Senior Managing Director, Doug Morrow and Senior M&A Advisor, Mike Moore, established the initial relationship with The Rockwall Center of Sensory Integration, Inc. dba Excel Pediatric Therapy. Ryan Binkley, CEO of Generational Group, stated, 'We're committed to delivering results that generate long-term value for all stakeholders. This milestone reflects the effectiveness of our strategy and the trust our clients consistently place in us.' About Generational Group Generational Group, headquartered in Dallas, TX, is a leading, award winning full-service M&A advisory firm. Generational has over 300 professionals across 16 offices in North America. The firm empowers business owners to unlock the full value of their companies through a comprehensive suite of services—including strategic growth consulting, exit planning education, business valuation, value enhancement strategies, M&A advisory, digital solutions, and wealth management. Celebrating its 20 th year, Generational has successfully closed over 1,700 transactions and has ranked #1 or #2 in all LSEG league tables for deals valued between $25 million and $1 billion in 2022, 2023, and 2024. The firm was named 2024 USA Investment Banking Firm of the Year by the Global M&A Network and recognized as Investment Banking Firm of the Year by The M&A Advisor in both 2024 and 2022.
